Abstract: A gastrostomy or nasogastric tube venting unit has a containment vessel for measuring fluids expelled with gastric gas before, during, after, or independent from feeding. The venting unit is particularly well-suited for pediatric or extremely weak patients who have difficulty producing sufficient pressure to expel gas through a fluid-filled feeding tube, including babies weighing less than 2000 grams. The venting unit includes a handle for suspending from an IV pole, a car or infant seat, stroller, a coat hook, or other support structures that might be used for travel. The containment vessel has a splash guard in the form of mesh material or screen covering or molded within the upper opening of the vessel, and can be capped temporarily for ease of transportation. The cap can be reopened when the patient is secured in a car seat or other means for travel, so that venting can resume.

Abstract: A gastrostomy or nasogastric tube venting unit has a containment vessel for measuring fluids expelled with gastric gas before, during, after, or independent from feeding. The venting unit is particularly well-suited for pediatric or extremely weak patients who have difficulty producing sufficient pressure to expel gas through a fluid-filled feeding tube, including babies weighing less than 2000 grams. The venting unit includes a handle for suspending from an IV pole, a car or infant seat, stroller, a coat hook, or other support structures that might be used for travel. The containment vessel has a splash guard in the form of mesh material or screen covering or molded within the upper opening of the vessel, and can be capped temporarily for ease of transportation. The cap can be reopened when the patient is secured in a car seat or other means for travel, so that venting can resume.

Abstract: Disclosed is a method of isolating, purifying, or concentrating a target compound. The method includes the steps of onjugating the target compound to an epitope for a polyol-responsive monoclonal antibody (PR-mAb) to yield a conjugate; and then contacting the conjugate to an immunoaffinity matrix comprising a PR-mAb specifically reactive with the PR-mAb epitope. Preferred epitopes for use in the method include amino acids of from 4 to about 30 amino acids, wherein the amino acid sequence comprises the sub-sequence D-X-S-R, (where X is any natural or unnatural amino acid), such as TKDPSRVG and TQDPSRVG. Additional epitopes for use in the method include SLAELLNGLGGS and PTSPSYSPTSPSYS. The method enables the rapid isolation of desired target compounds under gentle purification conditions.